According to a recent study conducted by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center, 76 percent of the adverse side effects (such as fatigue or headache) that people experienced after receiving their first COVID-19 vaccination were also reported by participants who received a placebo shot.

Syneos Health released the biopharmaceutical solutions organization’s report, 2022 Health Trends: Insights for Industry Change Agents. From patient-powered design to accelerated integration across the product lifecycle, the 2022 Trends report empowers organizations to be catalysts for change by anticipating what is to come, according to Syneos Health.

Total global spending on Covid-19 vaccines is projected to reach $157 billion by 2025, driven by mass vaccination programs underway and “booster shots” expected every two years, according to a report by U.S. health data company IQVIA Holdings Inc. released on April 29.

The likelihood that a coronavirus infection will prove fatal dropped by nearly a third since April due to improved treatment, researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME) said.

U.S. deaths from the coronavirus will reach 410,000 by the end of 2020 and deaths could soar to 3,000 per day in December, the University of Washington’s health institute forecast.

A University of Washington model projects the U.S. death toll from COVID-19 will climb to just above 224,000 by Nov. 1, up 16,000 from a prior forecast, due to rising infections and hospitalizations in many states.

The U.S. Food and Drug Administration approved Bausch Health Companies Inc.’s topical plaque psoriasis treatment Duobrii, which is expected to be a key revenue driver for the company.

Gilead Sciences Inc. announced that the company is providing $17.6 million in grants to 30 organizations in the United States through the Gilead HIV Age Positively initiative.

Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.

Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.